Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ASBP

Aspire Biopharma Holdings Inc

Jun 06 • 04:00PM ET

0.3805

Dollar change +0.0405
Percentage change 11.91	%

Healthcare • Biotechnology • USA • NASD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.71	Insider Own	20.42%	Shs Outstand	48.90M	Perf Week	-11.53%
Market Cap	18.85M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	39.41M	Perf Month	16.33%
Income	-26.01M	PEG	-	EPS next Q	-	Inst Own	2.90%	Short Float	0.22%	Perf Quarter	-55.76%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	85.71%	Short Ratio	0.01	Perf Half Y	-96.72%
Book/sh	-0.14	P/B	-	EPS next Y	-	ROA	-234.69%	Short Interest	0.09M	Perf Year	-96.73%
Cash/sh	0.03	P/C	13.96	EPS next 5Y	-	ROE	-490.07%	52W Range	0.22 - 15.80	Perf YTD	-96.69%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-97.59%	Beta	0.92
Dividend TTM	-	Quick Ratio	0.22	Sales past 5Y	-	Gross Margin	-	52W Low	76.98%	ATR (14)	0.10
Dividend Ex-Date	Jul 14, 2005	Current Ratio	0.22	EPS Y/Y TTM	-607.69%	Oper. Margin	-	RSI (14)	46.79	Volatility	10.28% 28.03%
Employees	-	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-53.32%	Payout	-	Rel Volume	0.20	Prev Close	0.34
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	12.28M	Price	0.38
SMA20	12.74%	SMA50	-11.72%	SMA200	-94.87%	Trades		Volume	2,481,637	Change	11.91%

May-29-25 08:45AM	Aspire Biopharma provides development update on BUZZ BOMB supplement (TipRanks) -14.72%
May-28-25 08:30AM	Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025 (ACCESSWIRE) +197.43%
May-20-25 08:30AM	Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation (ACCESSWIRE)
08:00AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE)
May-08-25 08:00AM	Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21 (ACCESSWIRE)
08:30AM	Loading…
Apr-29-25 08:30AM	Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation (ACCESSWIRE)
Apr-16-25 07:00AM	Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream (GlobeNewswire)
Apr-15-25 07:00AM	Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream (GlobeNewswire) -11.21%
Apr-14-25 08:30AM	Aspire Biopharma Holdings, Inc., to Present at the Emerging Growth Conference on Thursday, April 17 (ACCESSWIRE) +5.07%
Apr-11-25 08:30AM	Aspire Biopharma Holdings, Inc., Commences Initial Production of its Pre-Workout Performance Supplement (ACCESSWIRE) +11.32%
Apr-09-25 08:30AM	Aspire Biopharma Holdings, Inc., Announces Phase 1 Clinical Trial Initiation of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation (ACCESSWIRE) +16.17%
Mar-20-25 08:30AM	Aspire Biopharma Holdings, Inc., Contract Manufacturer, Glatt Air Techniques, Inc., has Completed Its First Good Manufacturing Practice ('GMP') Clinical Batch of Pharmaceutical Grade Oral Mucosal Fast Acting Formulation of Aspirin (ACCESSWIRE)
Mar-13-25 08:30AM	Aspire Biopharma Holdings, Inc., Provides Update on Recently Filed U.S. Patent Applications for Its Sublingual Drug Delivery Platform (ACCESSWIRE) -21.62%
Mar-11-25 08:00AM	An Interview with the CEO: How Aspire Biopharma is Disrupting a $100 Billion Market with Sublingual Innovation (Newsfile)
Mar-03-25 07:30AM	Aspire Biopharma Holdings, Inc., to Launch the Next Generation of Pre-Workout Performance Supplement (ACCESSWIRE) -32.67%
07:30AM	Loading…
Feb-25-25 07:30AM	Aspire Biopharma Holdings, Inc., Provides an Update on Lead Product Candidate: High-Dose, Sublingual Aspirin (ACCESS Newswire) -21.43%
Feb-20-25 06:15PM	Aspire Biopharma Holdings, Inc. Announces the Execution of Securities Purchase Agreement (ACCESSWIRE) -33.33% -58.44%
07:30AM	Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq (ACCESSWIRE)
Feb-19-25 01:10PM	Aspire Biopharma Holdings, Inc., Announces Public Listing on Nasdaq (ACCESSWIRE)
Sep-03-24 08:01AM	Aspire Biopharma, Inc., and PowerUp Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-listed Biopharmaceutical Company Driving Breakthrough Innovations in FDA Approved Drugs, Nutraceuticals and Supplements (GlobeNewswire)
Jul-31-24 08:01AM	Aspire Biopharma, Inc. Signs Letter of Intent to Create a Publicly Listed, Drug Delivery Company Through a Business Combination with PowerUp Acquisition Corp. (GlobeNewswire)
Jun-05-24 04:05PM	PowerUp Acquisition Corp. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q (GlobeNewswire)
May-20-24 05:11PM	PowerUp Acquisition Corp. Announces Postponement of Extraordinary General Meeting of Shareholders (GlobeNewswire)
May-16-24 04:05PM	PowerUp Acquisition Corp. Announces Postponement of Extraordinary General Meeting of Shareholders (GlobeNewswire) +7.62%
Jan-29-24 08:01AM	PowerUp Acquisition Corp. and Visiox Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form S-4 to the SEC in Connection with the Previously Announced Proposed Business Combination (GlobeNewswire)
Dec-27-23 08:01AM	Visiox Pharmaceuticals, Inc., a Commercial-Stage Biopharmaceutical Company to be Listed on Nasdaq Through a Business Combination with PowerUp Acquisition Corp. (GlobeNewswire)

Aspire Biopharma Holdings, Inc. operates as a biopharmaceutical company that engaged in developing and marketing a disruptive technology for drugs, nutraceuticals & supplements. The company was founded on February 2, 2025 and is headquartered in Humacao, Puerto Rico.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ASBP

Aspire Biopharma Holdings Inc

Upgrade your FINVIZ experience